Identification of risk factors on secondary hyperparathyroidism undergoing long-term haemodialysis with vitamin D3

D. Mizumoto, Y. Watanabe, Y. Fukuzawa, Yukio Yuzawa, C. Yamazaki

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

In order to evaluate the clinical outcome as well as the effect of vitamin D3 treatment on secondary hyperparathyroidism (SHPT) in the patients undergoing long-term dialysis therapy, we conducted a long-term follow-up survey on the demographic characteristics of 425 patients who were observed for more than 3 years. All patients were treated with daily 1±(OH)D3 treatment after the initiation of dialysis. Among them the percentage of patients needing parathyroidectomy was 4.9% aggravation of SHPT, 11.8% an increase of the parathyroid hormone (PTH) level without radiographical abnormalities, 17.4% stable, 56.2% and a decrease of the PTH level, 9.7% at the final observation. The average PTH levels increased year by year irrespective of the difference of original renal disease. Gender, age at the start of dialysis, original renal disease, duration of dialysis treatment, the decade of starting dialysis, the degree of phosphate control, and the PTH level at starting dialysis were analysed as potential risk factors for SHPT, and assessed by multivariate analysis. Multivariate analysis revealed that only the terms of duration of dialysis and the PTH level at starting dialysis were the significant risks for developing overt SHPT. Logistic regression analysis revealed that the relative risk was significantly higher in the patients with more than 10 years history of dialysis and in those with the carboxyterminal PTH levels at the start of dialysis being more than 5 ng/ml. These results suggest that the treatment with daily low-dose vitamin D3 administration after dialysis initiation is imperfect; therefore some prophylactic therapy from the predialysis stage is necessary to prevent overt SHPT, which will occur after long-term haemodialysis.

Original languageEnglish
Pages (from-to)1751-1758
Number of pages8
JournalNephrology Dialysis Transplantation
Volume9
Issue number12
DOIs
Publication statusPublished - 01-01-1994

Fingerprint

Secondary Hyperparathyroidism
Cholecalciferol
Renal Dialysis
Dialysis
Parathyroid Hormone
Therapeutics
Multivariate Analysis
Parathyroidectomy
Logistic Models
Phosphates
Regression Analysis
Observation
Demography
Kidney

All Science Journal Classification (ASJC) codes

  • Nephrology
  • Transplantation

Cite this

@article{77f3ddb7eb894d8a8c8b3b3af4da4689,
title = "Identification of risk factors on secondary hyperparathyroidism undergoing long-term haemodialysis with vitamin D3",
abstract = "In order to evaluate the clinical outcome as well as the effect of vitamin D3 treatment on secondary hyperparathyroidism (SHPT) in the patients undergoing long-term dialysis therapy, we conducted a long-term follow-up survey on the demographic characteristics of 425 patients who were observed for more than 3 years. All patients were treated with daily 1±(OH)D3 treatment after the initiation of dialysis. Among them the percentage of patients needing parathyroidectomy was 4.9{\%} aggravation of SHPT, 11.8{\%} an increase of the parathyroid hormone (PTH) level without radiographical abnormalities, 17.4{\%} stable, 56.2{\%} and a decrease of the PTH level, 9.7{\%} at the final observation. The average PTH levels increased year by year irrespective of the difference of original renal disease. Gender, age at the start of dialysis, original renal disease, duration of dialysis treatment, the decade of starting dialysis, the degree of phosphate control, and the PTH level at starting dialysis were analysed as potential risk factors for SHPT, and assessed by multivariate analysis. Multivariate analysis revealed that only the terms of duration of dialysis and the PTH level at starting dialysis were the significant risks for developing overt SHPT. Logistic regression analysis revealed that the relative risk was significantly higher in the patients with more than 10 years history of dialysis and in those with the carboxyterminal PTH levels at the start of dialysis being more than 5 ng/ml. These results suggest that the treatment with daily low-dose vitamin D3 administration after dialysis initiation is imperfect; therefore some prophylactic therapy from the predialysis stage is necessary to prevent overt SHPT, which will occur after long-term haemodialysis.",
author = "D. Mizumoto and Y. Watanabe and Y. Fukuzawa and Yukio Yuzawa and C. Yamazaki",
year = "1994",
month = "1",
day = "1",
doi = "10.1093/oxfordjournals.ndt.a092757",
language = "English",
volume = "9",
pages = "1751--1758",
journal = "Nephrology Dialysis Transplantation",
issn = "0931-0509",
publisher = "Oxford University Press",
number = "12",

}

Identification of risk factors on secondary hyperparathyroidism undergoing long-term haemodialysis with vitamin D3. / Mizumoto, D.; Watanabe, Y.; Fukuzawa, Y.; Yuzawa, Yukio; Yamazaki, C.

In: Nephrology Dialysis Transplantation, Vol. 9, No. 12, 01.01.1994, p. 1751-1758.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Identification of risk factors on secondary hyperparathyroidism undergoing long-term haemodialysis with vitamin D3

AU - Mizumoto, D.

AU - Watanabe, Y.

AU - Fukuzawa, Y.

AU - Yuzawa, Yukio

AU - Yamazaki, C.

PY - 1994/1/1

Y1 - 1994/1/1

N2 - In order to evaluate the clinical outcome as well as the effect of vitamin D3 treatment on secondary hyperparathyroidism (SHPT) in the patients undergoing long-term dialysis therapy, we conducted a long-term follow-up survey on the demographic characteristics of 425 patients who were observed for more than 3 years. All patients were treated with daily 1±(OH)D3 treatment after the initiation of dialysis. Among them the percentage of patients needing parathyroidectomy was 4.9% aggravation of SHPT, 11.8% an increase of the parathyroid hormone (PTH) level without radiographical abnormalities, 17.4% stable, 56.2% and a decrease of the PTH level, 9.7% at the final observation. The average PTH levels increased year by year irrespective of the difference of original renal disease. Gender, age at the start of dialysis, original renal disease, duration of dialysis treatment, the decade of starting dialysis, the degree of phosphate control, and the PTH level at starting dialysis were analysed as potential risk factors for SHPT, and assessed by multivariate analysis. Multivariate analysis revealed that only the terms of duration of dialysis and the PTH level at starting dialysis were the significant risks for developing overt SHPT. Logistic regression analysis revealed that the relative risk was significantly higher in the patients with more than 10 years history of dialysis and in those with the carboxyterminal PTH levels at the start of dialysis being more than 5 ng/ml. These results suggest that the treatment with daily low-dose vitamin D3 administration after dialysis initiation is imperfect; therefore some prophylactic therapy from the predialysis stage is necessary to prevent overt SHPT, which will occur after long-term haemodialysis.

AB - In order to evaluate the clinical outcome as well as the effect of vitamin D3 treatment on secondary hyperparathyroidism (SHPT) in the patients undergoing long-term dialysis therapy, we conducted a long-term follow-up survey on the demographic characteristics of 425 patients who were observed for more than 3 years. All patients were treated with daily 1±(OH)D3 treatment after the initiation of dialysis. Among them the percentage of patients needing parathyroidectomy was 4.9% aggravation of SHPT, 11.8% an increase of the parathyroid hormone (PTH) level without radiographical abnormalities, 17.4% stable, 56.2% and a decrease of the PTH level, 9.7% at the final observation. The average PTH levels increased year by year irrespective of the difference of original renal disease. Gender, age at the start of dialysis, original renal disease, duration of dialysis treatment, the decade of starting dialysis, the degree of phosphate control, and the PTH level at starting dialysis were analysed as potential risk factors for SHPT, and assessed by multivariate analysis. Multivariate analysis revealed that only the terms of duration of dialysis and the PTH level at starting dialysis were the significant risks for developing overt SHPT. Logistic regression analysis revealed that the relative risk was significantly higher in the patients with more than 10 years history of dialysis and in those with the carboxyterminal PTH levels at the start of dialysis being more than 5 ng/ml. These results suggest that the treatment with daily low-dose vitamin D3 administration after dialysis initiation is imperfect; therefore some prophylactic therapy from the predialysis stage is necessary to prevent overt SHPT, which will occur after long-term haemodialysis.

UR - http://www.scopus.com/inward/record.url?scp=0028586028&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028586028&partnerID=8YFLogxK

U2 - 10.1093/oxfordjournals.ndt.a092757

DO - 10.1093/oxfordjournals.ndt.a092757

M3 - Article

C2 - 7708259

AN - SCOPUS:0028586028

VL - 9

SP - 1751

EP - 1758

JO - Nephrology Dialysis Transplantation

JF - Nephrology Dialysis Transplantation

SN - 0931-0509

IS - 12

ER -